Pan-Amyloid Depleter (Lead PAR Therapeutic)
Systemic Amyloidosis (all types: ATTR, AL, AA, etc.)
Phase 1/2Active - Data presented at ASH 2025
Key Facts
Indication
Systemic Amyloidosis (all types: ATTR, AL, AA, etc.)
Phase
Phase 1/2
Status
Active - Data presented at ASH 2025
Company
About Attralus
Attralus is pioneering a transformative approach to systemic amyloidosis with its pan-amyloid removal (PAR) platform, which targets the underlying disease pathology by clearing toxic amyloid deposits from vital organs. The company's strategy is built on deep amyloid research expertise and includes both therapeutic biologics and a proprietary diagnostic imaging agent. With a lead program in Phase 1/2 trials and backing from prominent life science investors like venBio and Sarissa Capital, Attralus is positioned to potentially shift the treatment paradigm from slowing progression to enabling disease reversal.
View full company profile